Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Colorectal Neoplasms 3Carcinoma, Renal Cell 2Solid Tumors 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1

Interventions

Cetuximab 5pembrolizumab 3Injections 3Bevacizumab 2taxane 1ribociclib 1pegylated granulocyte colony-stimulating factor 1olaparib 1fludarabine phosphate 1fludarabine 1encorafenib 1dapagliflozin 1cemiplimab 1binimetinib 1anlotinib 1amivantamab 1adagrasib 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Irinotecan 1Immunotherapy, Adoptive 1IFL protocol 1Folfox protocol 1Fluorouracil 1Filgrastim 1Docetaxel 1Cyclophosphamide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Solid Tumors × adagrasib × Clear all
NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Mirati Therapeutics Inc.

Phase 2 Recruiting
170 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡